Wall Street’s Key Stock Analysts Research Report, All Buys

Wall Street’s Key Stock Analysts Research Report, All Buys

#stocks #bullish #buys #analysts #research #WallStreet

$CRSP $FIVE $ITCI $LEVI $DIS

These are all Buys if you can manage the risk.

Daily HeffX-LTN reviews dozens of Wall Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers. These reports cover stocks to buy

Below are our Buy calls for Friday, 11 December, as follows:

CRISPR Therapeutics A.G. (NASDAQ:CRSP) was reiterated as Buy and its price target was raised to 170 from 105 at Needham. Shares have a 122.63 consensus target price.

Five Below Inc. (NASDAQ:FIVE) was raised to Buy from Neutral with a 194 price target at Goldman Sachs.

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) was started with a Buy rating and a 38 price target at Goldman Sachs.

Levi Strass & Co. (NYSE:LEVI) was raised to Buy from Sell with a 23 price target at Goldman Sachs.

Walt Disney Co. (NYSE:DIS) was started with a Buy rating and a 175 price target at Stephens.

Have a healthy weekend, Keep the Faith!

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, a polymath, excels, in diverse fields of knowledge Including Pattern Recognition Analysis in Equities, Commodities and Foreign Exchange, and he is the author of "The Red Roadmaster's Technical Report on the US Major Market Indices, a highly regarded, weekly financial market commentary. He is a philosopher, issuing insights on a wide range of subjects to over a million cohorts. An international audience of opinion makers, business leaders, and global organizations recognize Ebeling as an expert.